scholarly journals Crystal Methamphetamine Use and Initiation among Gay, Bisexual, and Other Men Who Have Sex with Men Living with HIV in a Treatment as Prevention Environment

2020 ◽  
Vol 55 (14) ◽  
pp. 2428-2437
Author(s):  
Sean P. Colyer ◽  
David M. Moore ◽  
Zishan Cui ◽  
Julia Zhu ◽  
Heather L. Armstrong ◽  
...  
Author(s):  
Dr. Daniel Cebo

Crystal methamphetamine is an extremely addictive stimulant that increases sexual arousal while reducing inhibition and judgment. Its use is associated with a range of high-risk sexual behaviors that increase the likelihood of acquiring or transmitting HIV. Given the relatively high prevalence of crystal methamphetamine use among people living with HIV and among men who have sex with men, there is great concern that this drug is fueling the HIV epidemic. Equally worrisome are the effects that crystal methamphetamine use can have on the prognosis and overall health of HIV-infected patients. This article reports the results of a pilot study that is part of a larger project exploring the correlates of antiretroviral therapy drug resistance.


2010 ◽  
Vol 87 (3) ◽  
pp. 480-485 ◽  
Author(s):  
David W. Forrest ◽  
Lisa R. Metsch ◽  
Marlene LaLota ◽  
Gabriel Cardenas ◽  
Dano W. Beck ◽  
...  

Sexual Health ◽  
2014 ◽  
Vol 11 (2) ◽  
pp. 146 ◽  
Author(s):  
James Jansson ◽  
Cliff C. Kerr ◽  
David P. Wilson

Introduction The treatment as prevention strategy has gained popularity as a way to reduce the incidence of HIV by suppressing viral load such that transmission risk is decreased. The effectiveness of the strategy also requires early diagnosis. Methods: Informed by data on the influence of diagnosis and treatment on reducing transmission risk, a model simulated the impact of increasing testing and treatment rates on the expected incidence of HIV in Australia under varying assumptions of treatment efficacy and risk compensation. The model utilises Australia’s National HIV Registry data, and simulates disease progression, testing, treatment, transmission and mortality. Results: Decreasing the average time between infection and diagnosis by 30% is expected to reduce population incidence by 12% (~126 cases per year, 95% confidence interval (CI): 82–198). Treatment of all people living with HIV with CD4 counts <500 cells μL–1 is expected to reduce new infections by 30.9% (95% CI: 15.9–37.6%) at 96% efficacy if no risk compensation occurs. The number of infections could increase up to 12.9% (95% CI: 20.1–7.4%) at 26% efficacy if a return to prediagnosis risk levels occur. Conclusion: Treatment as prevention has the potential to prevent HIV infections but its effectiveness depends on the efficacy outside trial settings among men who have sex with men and the level of risk compensation. If antiretroviral therapy has high efficacy, risk compensation will not greatly change the number of infections. If the efficacy of antiretroviral therapy is low, risk compensation could lead to increased infections.


2019 ◽  
Vol 10 ◽  
Author(s):  
Henrike Schecke ◽  
Toby Lea ◽  
Annette Bohn ◽  
Thorsten Köhler ◽  
Dirk Sander ◽  
...  

2016 ◽  
Vol 36 ◽  
pp. 43-46 ◽  
Author(s):  
G.J. Melendez-Torres ◽  
Chris Bonell ◽  
Ford Hickson ◽  
Adam Bourne ◽  
David Reid ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document